AUROPHARMA.NS Aurobindo Pharma Limited
INR·Price 1396.50·Mkt cap 803.52BComputed from the latest reported financials and the current market price.
Who's the real player?
A genuine play on this theme — most of its business sits right here.
Is the business healthy?
A mixed picture — real strengths, but soft spots in cash flow, returns or debt.
- ⚠Receivables growing much faster than revenue (channel-stuffing risk)
- Strong cash flow quality
- High FCF conversion
- Low accrual ratio
Are the smart people buying?
No ownership-change data for this stock. Conviction is judged from capex and buyback signals alone.
- Strong promoter/insider stake
- Capex growth indicates belief in future
- Institutional holdings remain stable
What is management saying?
No earnings-call transcript or filings found for this stock.
Is the price right?
Intrinsic value 605.16 vs price 1396.50 — screens expensive on a cash-flow DCF (-56.7% to intrinsic). The base FCF growth assumption of 8% appears high for most industries and may not be sustainable without strong evidence.
| Intrinsic / share | 605.16 |
| Price | 1396.50 |
| Upside to intrinsic | -56.7% |
| Reverse-DCF implied g | 19.3% |
Base FCF 19.13B · growth 8.0% · discount 12.0% · terminal 5.0%.
Sensitivity — intrinsic value / share
Each cell is the intrinsic value at that growth (across →) and discount rate (down ↓). Center ★ is the base case. Cells green = above price (cheap), red = below (expensive).
| Growth rate → | |||||
|---|---|---|---|---|---|
| Disc ↓ ╲ g | 4% | 6% | 8% | 10% | 12% |
| 10% | 630.68 | 739.64 | 866.99 | 1015.57 | 1188.58 |
| 11% | 524.56 | 612.07 | 714.07 | 832.78 | 970.71 |
| 12% | 448.69 | 521.04 | ★ 605.16 | 702.82 | 816.04 |
| 13% | 391.71 | 452.85 | 523.73 | 605.83 | 700.8 |
| 14% | 347.35 | 399.87 | 460.61 | 530.79 | 611.8 |
Through the masters' eyes
Each investor's numeric rules, checked against this stock's metrics: exact math, no guesswork. Tap one to see which rules pass, fail, and what to judge yourself.
▶
Passes 2 of 2 of Peter Lynch's numeric checks. Still judge the non-numeric criteria below for yourself.
- Manageable debt (D/E ≤ 1.0) — now 0.21
- Solid liquidity (current ratio ≥ 1.5) — now 1.81
- A simple business you understand
- Which 'type' it is (fast grower, stalwart, cyclical…)
- A believable growth story
Couldn't check from available data: PEG ≤ 1 (growth cheap vs price) — not available; Earnings growth ≥ 15% — not available
▶
Passes 3 of 4 of Radhakishan Damani's numeric checks. Still judge the non-numeric criteria below for yourself.
- Very low debt (D/E ≤ 0.5) — now 0.21
- Consistent revenue (consistency ≥ 80%) — now 95.7%
- Positive net margin — now 10.5%
- High returns on capital (ROCE ≥ 18%) — now 12.5%
- A durable consumer franchise
- Pricing power
- A long runway, bought patiently
▶
Passes 2 of 3 of Rakesh Jhunjhunwala's numeric checks. Still judge the non-numeric criteria below for yourself.
- Net margin ≥ 10% — now 10.5%
- Conservative leverage (D/E ≤ 1.0) — now 0.21
- ROE ≥ 18% — now 9.2%
- A large, scalable opportunity
- Trustworthy, ambitious management
- Conviction to hold through volatility
Couldn't check from available data: Earnings growth ≥ 15% — not available
▶
Passes 3 of 5 of Warren Buffett's numeric checks. Still judge the non-numeric criteria below for yourself.
- Net margin ≥ 10% — now 10.5%
- Positive free cash flow — now 7.3%
- Conservative leverage (D/E ≤ 1.0) — now 0.21
- ROE ≥ 15% — now 9.2%
- Trades below intrinsic value (margin of safety ≥ 0) — now -130.8%
- A business you can understand
- A durable competitive moat
- Honest, capable management
▶
Passes 3 of 6 of Benjamin Graham's numeric checks. Still judge the non-numeric criteria below for yourself.
- Strong liquidity (current ratio ≥ 1.5) — now 1.81
- Debt below equity (D/E ≤ 1.0) — now 0.21
- Financially safe (Altman Z ≥ 3) — now 3.91
- P/E ≤ 15 — now 22.96
- P/B ≤ 1.5 — now 2.12
- Graham number: P/E × P/B ≤ 22.5 — now 48.7
- A long record of stable earnings
- An uninterrupted dividend history
▶
Passes 1 of 2 of Raamdeo Agrawal's numeric checks. Still judge the non-numeric criteria below for yourself.
- Longevity: revenue consistency ≥ 70% — now 95.7%
- Quality: ROCE ≥ 18% — now 12.5%
- Durability of the growth (longevity)
- Quality and honesty of management
Couldn't check from available data: Growth: earnings CAGR ≥ 15% — not available; Price: PEG ≤ 2 — not available
▶
Passes 1 of 2 of Vijay Kedia's numeric checks. Still judge the non-numeric criteria below for yourself.
- Manageable debt (D/E ≤ 1.0) — now 0.21
- ROE ≥ 15% — now 9.2%
- Ambitious, capable management
- A small company with a large opportunity
- Patience to hold for years
Couldn't check from available data: Strong earnings growth ≥ 20% — not available
▶
Passes 1 of 4 of Charlie Munger's numeric checks. Still judge the non-numeric criteria below for yourself.
- Conservative leverage (D/E ≤ 1.0) — now 0.21
- High returns on capital (ROCE ≥ 15%) — now 12.5%
- ROE ≥ 15% — now 9.2%
- Trades below intrinsic value (margin of safety ≥ 0) — now -130.8%
- A high-quality, understandable business
- A durable moat
- Management of integrity
Financial statements (INR)
↗ sourceCash-flow lines highlighted — we trust cash over reported profit.
| Line | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 333.85B | 313.78B | 287.05B | 246.17B | — |
| Operating income | 50.78B | 49.56B | 44.42B | 25.38B | — |
| EBITDA | 72.74B | 71.73B | 61.40B | 39.86B | — |
| Net income | 35.05B | 34.86B | 31.73B | 19.27B | — |
| Operating cash flow | 55.26B | 39.25B | 24.35B | 23.87B | — |
| Capex | -31.05B | -25.20B | -35.62B | -27.20B | — |
| Free cash flow | 24.22B | 14.05B | -11.27B | -3.34B | — |
| Total assets | 585.02B | 497.85B | 450.72B | 398.90B | — |
| Total equity | 378.91B | 326.53B | 298.43B | 268.40B | — |
| Total debt | 80.73B | 82.63B | 66.48B | 52.86B | — |
| Cash & equivalents | 71.91B | 55.69B | 33.93B | 43.96B | — |